Daratumumab is a subcutaneously administered, anti-CD38 monoclonal antibody already approved for multiple myeloma, which is able to induce apoptosis in CD38 highly expressing cells (Table 6 and Table 7). This evidence concerns the gene CD38 and AL amyloidosis.